GANDOLFO, CLAUDIA
 Distribuzione geografica
Continente #
NA - Nord America 3.469
EU - Europa 3.237
AS - Asia 1.633
SA - Sud America 310
Continente sconosciuto - Info sul continente non disponibili 160
AF - Africa 114
OC - Oceania 5
Totale 8.928
Nazione #
US - Stati Uniti d'America 3.370
IT - Italia 745
RU - Federazione Russa 735
SG - Singapore 529
IE - Irlanda 496
GB - Regno Unito 409
CN - Cina 368
VN - Vietnam 292
BR - Brasile 241
SE - Svezia 188
DE - Germania 165
FR - Francia 147
HK - Hong Kong 139
FI - Finlandia 110
UA - Ucraina 66
IN - India 65
ZA - Sudafrica 58
KR - Corea 52
CA - Canada 38
BD - Bangladesh 37
PL - Polonia 33
ES - Italia 29
NL - Olanda 28
TR - Turchia 25
MX - Messico 21
BE - Belgio 19
AR - Argentina 16
CO - Colombia 16
PK - Pakistan 16
JP - Giappone 15
IQ - Iraq 14
NG - Nigeria 13
AT - Austria 12
CI - Costa d'Avorio 11
SA - Arabia Saudita 11
AE - Emirati Arabi Uniti 10
EC - Ecuador 9
ID - Indonesia 9
IM - Isola di Man 9
CR - Costa Rica 8
CZ - Repubblica Ceca 8
TT - Trinidad e Tobago 8
IL - Israele 7
MA - Marocco 7
CL - Cile 6
EG - Egitto 6
PE - Perù 6
VE - Venezuela 6
HN - Honduras 5
KE - Kenya 5
LT - Lituania 5
PT - Portogallo 5
TN - Tunisia 5
UZ - Uzbekistan 5
BG - Bulgaria 4
DZ - Algeria 4
GT - Guatemala 4
IR - Iran 4
MT - Malta 4
PY - Paraguay 4
UY - Uruguay 4
AU - Australia 3
CH - Svizzera 3
EU - Europa 3
JM - Giamaica 3
JO - Giordania 3
KZ - Kazakistan 3
MY - Malesia 3
NP - Nepal 3
PS - Palestinian Territory 3
TH - Thailandia 3
AL - Albania 2
AM - Armenia 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
HU - Ungheria 2
KG - Kirghizistan 2
KH - Cambogia 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PH - Filippine 2
PR - Porto Rico 2
RO - Romania 2
SV - El Salvador 2
AG - Antigua e Barbuda 1
AO - Angola 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
HR - Croazia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
Totale 8.761
Città #
Dublin 480
Ashburn 335
Dallas 328
Singapore 325
Southend 308
Chandler 218
San Jose 218
Fairfield 204
Moscow 204
Santa Clara 190
Siena 164
Milan 139
Hong Kong 128
Beijing 107
Council Bluffs 102
Wilmington 91
Ho Chi Minh City 81
New York 79
Houston 78
Los Angeles 78
Rome 76
Ann Arbor 75
Woodbridge 74
Cambridge 71
Seattle 69
Princeton 68
Helsinki 67
Hanoi 62
The Dalles 59
Munich 58
Jacksonville 53
Seoul 50
Lauterbourg 48
Hefei 46
Johannesburg 46
Florence 35
Warsaw 31
Fremont 28
Dong Ket 25
São Paulo 25
Menlo Park 24
Buffalo 22
Chicago 20
Da Nang 20
Frankfurt am Main 20
Shanghai 19
Atlanta 17
Columbus 17
San Mateo 17
Turku 17
Brussels 16
Boardman 15
Montreal 15
Chennai 14
Málaga 14
San Diego 14
Tokyo 14
Haiphong 13
London 13
Nanjing 13
Redondo Beach 13
Abuja 12
Lancaster 12
Lappeenranta 12
Newark 12
Nuremberg 12
Orem 12
Turin 12
Abidjan 11
Figino 11
Boston 10
Düsseldorf 10
Izmir 10
Phoenix 10
Portsmouth 10
Dearborn 9
Denver 9
Falls Church 9
Rio de Janeiro 9
Toronto 9
Douglas 8
North Bergen 8
Poplar 8
Washington 8
Bengaluru 7
Biên Hòa 7
Brooklyn 7
Columbia 7
Dubai 7
Karlsruhe 7
Messina 7
Shenyang 7
Baghdad 6
Cagliari 6
Dhaka 6
Espoo 6
Hải Dương 6
Jeddah 6
Mexico City 6
Norwalk 6
Totale 5.607
Nome #
A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease 402
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients 350
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine 339
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients 304
Host-pathogen interaction: study of Toscana virus 299
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients 292
Antibody response to SARS-CoV-2 in infected patients with different clinical outcome 291
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). 286
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 283
Whole-Genome Sequence of SARS-CoV-2 Isolate Siena-1/2020 256
Seroprevalence to measles virus after vaccination or natural infection in an adult population, in Italy 240
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 235
Identification of a neutralizing epitope on tosv gn glycoprotein 229
Immune-inflammatory markers predict the outcome of metastatic colorectal cancer patients treated with the thymidylate synthase poly-epitope peptide (TSPP) vaccine: results from a multi-arm TSPP/VAC phase lb program 226
Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: Results from a large-scale screening program based on rapid serological testing 226
Infection prevention in endoscopy practice; comparative evaluation of reusable vs single use endoscopic valves 216
Human Polymorphonuclear Cells Support Zika Virus to Cross Endothelial Monolayer and Access Bloodstream 216
Omicron infection evokes cross-protection against SARS-CoV-2 variants in vaccinees 209
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 202
Efficient inactivation of sars-cov-2 and other rna or dna viruses with blue led light 199
SARS-CoV-2 Antibody Response in Persons with Past Natural Infection 195
Alcohol intake and the risk of intracerebral hemorrhage in the elderly: The MUCH-Italy 194
Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era 194
Ubiquitin and not only unfolded domains drives toscana virus non-structural NSs protein degradation 190
Comparative performance of a new sars-cov-2 rapid detection system 190
Neutralizing antibody response of vaccinees to SARS-CoV-2 variants 187
Toscana virus non-structural protein NSs acts as E3 ubiquitin ligase promoting RIG-I degradation 185
Infectious Toscana virus in seminal fluid of young man returning from Elba Island, Italy 185
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 182
Nucleopore Traffic Is Hindered by SARS-CoV-2 ORF6 Protein to Efficiently Suppress IFN-β and IL-6 Secretion 181
How long can SARS-CoV-2 persist in human corpses? 180
Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience 180
Epidemiology of Toscana virus in South Tuscany over the years 2011-2019 176
Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine 172
Toscana virus infects dendritic and endothelial cells opening the way for the central nervous system 164
Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified? 157
SARS-CoV-2 n protein targets TRIM25-mediated RIG-I activation to suppress innate immunity 144
Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix 126
Detection of SARS-CoV-2 N protein allelic variants by rapid high-throughput CLEIA antigen assay 124
Truncation of the C-terminal region of Toscana Virus NSs protein is critical for interferon-β antagonism and protein stability 110
Validation of Two Commercial Multiplex Real-Time PCR Assays for Detection of SARS-CoV-2 in Stool Donors for Fecal Microbiota Transplantation 109
null 103
Totale 8.928
Categoria #
all - tutte 30.665
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.665


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022399 0 0 0 0 23 27 21 16 99 45 57 111
2022/2023758 42 92 98 80 75 154 18 74 59 25 25 16
2023/2024862 24 51 70 47 35 212 307 24 7 14 16 55
2024/20251.440 57 61 158 94 163 98 94 94 160 80 157 224
2025/20263.375 228 383 282 460 733 139 450 86 129 209 87 189
2026/2027546 82 80 166 195 23 0 0 0 0 0 0 0
Totale 8.928